Crossmark

Predictive factors for first dose reduction and interruption of lenvatinib after beginning of the standard dose in Japanese patients with thyroid cancer

Crossref DOI link: https://doi.org/10.1007/s00280-024-04729-6

Published Online: 2024-12-19

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fujita, Kazuma

Nagahama, Mitsuji

Suzuki, Akifumi

Masaki, Chie

Sugino, Kiminori

Ito, Koichi

Miura, Masatomo
Funding

Funding for this research was provided by:

Japan Society for the Promotion of Science (20K07150)
License Information

Text and Data Mining valid from 2024-12-19

Version of Record valid from 2024-12-19
More Information

Article History

Received: 5 July 2024

Accepted: 10 October 2024

First Online: 19 December 2024

Declarations

:

: All authors have no conflicts of interest. The authors declare no competing interests.

: The study was performed in accordance with the ethical standards of the Declaration of Helsinki and its subsequent amendments.

: Signed informed consent was obtained from all patients.

Document is current

Any future updates will be listed below